HONOLULU, HI, UNITED STATES, January 29, 2026 /EINPresswire.com/ -- PTC, a global non profit advancing digital ...

PTC Therapeutics, Inc. PTCT closed lower on Thursday following the company’s decision to withdraw its New Drug Application ...

In a statement, PTC's chief executive, Matthew Klein, said the company had decided to pull the filing for Translarna (ataluren) as a treatment for nonsense mutation DMD after the FDA said it was ...

Honorees recognized at PTC’s largest annual conference in its 48 year history Each recipient is contributing in ...

This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...

Following FDA feedback, PTC Therapeutics withdrew its application for ataluren, intended for the treatment of nonsense mutation Duchenne muscular dystrophy.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for ...

Why PTC Stock Is Back in Focus After Earnings and New Client Win PTC (PTC) is back on many investors radar after a combination of better than expected quarterly results, higher full year guidance, and ...

PTC (NasdaqGS:PTC) has been selected by SPG Company to provide its FlexPLM solution. SPG Company is replacing its legacy product lifecycle management system with PTC's cloud based FlexPLM platform.

Enables faster, more collaborative product execution with a cloud-based PLM solution built to support future growth BOSTON, ...